Skip to content
2000
Volume 24, Issue 2
  • ISSN: 2211-3525
  • E-ISSN: 2211-3533

Abstract

Mucormycosis is an aggressive and often fatal fungal infection, posing a significant challenge in immunocompromised patients, particularly those with diabetes, cancer, or post-organ transplantation. Despite available antifungal treatments such as amphotericin B, posaconazole, and isavuconazole, mortality rates remain high, highlighting the need for early diagnosis and aggressive intervention. This review explores current therapeutic strategies, including antifungal therapy, and the critical role of surgical intervention in improving outcomes. Additionally, it examines innovative drug delivery systems, such as nanoparticle-based formulations and liposomal encapsulation, designed to enhance drug efficacy while minimizing toxicity. The recent surge in mucormycosis cases, particularly during the COVID-19 pandemic, emphasizes the urgent need for improved awareness, early detection, and optimized treatment protocols. Advancements in diagnostic techniques and emerging therapeutic approaches offer hope for better management of this deadly infection. By analyzing current trends and future directions, this article advocates for a multidisciplinary approach that combines clinical expertise with cutting-edge research. Strengthening collaborative efforts in diagnosis, treatment, and drug development is essential to reducing mortality and improving patient outcomes in this rare but life-threatening disease.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/aia/10.2174/0122113525373696250623070215
2025-07-04
2026-03-09

  • From This Site

    /content/journals/aia/10.2174/0122113525373696250623070215
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. VasaniA. MistryS. ShahR. Exponential rise of fungal infection reported in rajkot civil hospital in covid pandemic era: A retrospective study.Indian J. Otolaryngol. Head Neck Surg.20247611410.1007/s12070‑023‑03743‑z 38440567
     [Google Scholar]
  2. SigeraL.S.M. DenningD.W. A systematic review of the therapeutic outcome of mucormycosis.Open Forum Infectious Diseases.USOxford University Press202410.1093/ofid/ofad704
     [Google Scholar]
  3. DivakarP.K. Fungal taxa responsible for mucormycosis/“black fungus” among COVID-19 patients in India.J. Fungi20217864110.3390/jof7080641 34436180
     [Google Scholar]
  4. ChangC.C. HarrisonT.S. BicanicT.A. ChayakulkeereeM. SorrellT.C. WarrisA. HagenF. SpecA. OladeleR. GovenderN.P. ChenS.C. ModyC.H. GrollA.H. ChenY.C. LionakisM.S. AlanioA. CastañedaE. LizarazoJ. VidalJ.E. TakazonoT. HoeniglM. AlffenaarJ.W. GangneuxJ.P. SomanR. ZhuL.P. BonifazA. JarvisJ.N. DayJ.N. KlimkoN. Salmanton-GarcíaJ. JouvionG. MeyaD.B. LawrenceD. RahnS. BongominF. McMullanB.J. SpruteR. NyazikaT.K. BeardsleyJ. CarlesseF. HeathC.H. AyanlowoO.O. MashediO.M. Queiroz-Telles FilhoF. HosseinipourM.C. PatelA.K. TemfackE. SinghN. CornelyO.A. BoulwareD.R. LortholaryO. PappasP.G. PerfectJ.R. Global guideline for the diagnosis and management of cryptococcosis: An initiative of the ECMM and ISHAM in cooperation with the ASM.Lancet Infect. Dis.2024248e495e51210.1016/S1473‑3099(23)00731‑4 38346436
     [Google Scholar]
  5. HanG. XuQ. LvQ. LiX. ShiX. Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: Initial therapy prior to pathogen differential diagnosis in China.Front. Public Health202311129216210.3389/fpubh.2023.1292162 38179563
     [Google Scholar]
  6. DidehdarM. cheginiZ. MoradabadiA. AnoushirvaniA.A. TabaeianS.P. YousefimashoufM. ShariatiA. Gastrointestinal mucormycosis: A periodic systematic review of case reports from 2015 to 2021.Microb. Pathog.202216310538810.1016/j.micpath.2022.105388 34995749
     [Google Scholar]
  7. MorenoI. The diagnosis of chronic endometritis in infertile asymptomatic women: A comparative study of histology, microbial cultures, hysteroscopy, and molecular microbiology.Am. J. Obstet. Gynecol.20182186602.e1602.e1610.1016/j.ajog.2018.02.012 29477653
     [Google Scholar]
  8. ChikleyA. Ben-AmiR. KontoyiannisD.P. Mucormycosis of the central nervous system.J. Fungi2019535910.3390/jof5030059 31288475
     [Google Scholar]
  9. LouisT.J. QasemA. AbdelliL.S. NaserS.A. Extra-pulmonary complications in SARS-CoV-2 infection: A comprehensive multi organ-system review.Microorganisms202210115310.3390/microorganisms10010153 35056603
     [Google Scholar]
  10. DanionF. CosteA. Le HyaricC. MelenotteC. LamothF. CalandraT. Garcia-HermosoD. AimaniandaV. LanternierF. LortholaryO. What is new in pulmonary mucormycosis?J. Fungi20239330710.3390/jof9030307 36983475
     [Google Scholar]
  11. KantarciogluA.S. Mucormycosis.Fungal Infections of the Central Nervous System.ChamSpringer201912115410.1007/978‑3‑030‑06088‑6_10
     [Google Scholar]
  12. PerfectJ.R. Fungal diagnosis: How do we do it and can we do better?Curr. Med. Res. Opin.201329Suppl. 431110.1185/03007995.2012.761134 23621588
     [Google Scholar]
  13. SerrisA. DanionF. LanternierF. Disease entities in mucormycosis.J. Fungi2019512310.3390/jof5010023 30875744
     [Google Scholar]
  14. SkiadaA. Drogari-ApiranthitouM. PavleasI. DaikouE. PetrikkosG. Global cutaneous mucormycosis: A systematic review.J. Fungi20228219410.3390/jof8020194 35205948
     [Google Scholar]
  15. BonifazA. Tirado-SánchezA. CalderónL. PonceR.M. Cutaneous mucormycosis: Mycological, clinical, and therapeutic aspects.Curr. Fungal Infect. Rep.20159422923710.1007/s12281‑015‑0236‑z
     [Google Scholar]
  16. SpellbergB. MaertensJ. Mucormycosis.Principles and Practice of Transplant Infectious Diseases.New York, NYSpringer2019577589
     [Google Scholar]
  17. BlythC.C. GilroyN.M. GuyS.D. ChambersS.T. CheongE.Y. GottliebT. McGuinnessS.L. ThurskyK.A. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.Intern. Med. J.20144412b1333134910.1111/imj.12598 25482744
     [Google Scholar]
  18. BurrellC.J. HowardC.R. MurphyF.A. Pathogenesis of virus infections.Fenner and White’s Medical Virology.Cambridge, MassachusettsAcademic Press20177710410.1016/B978‑0‑12‑375156‑0.00007‑2
     [Google Scholar]
  19. SkiadaA. PavleasI. Drogari-ApiranthitouM. Epidemiology and diagnosis of mucormycosis: An update.J. Fungi20206426510.3390/jof6040265 33147877
     [Google Scholar]
  20. PanJ. TsuiC. LiM. XiaoK. de HoogG.S. VerweijP.E. CaoY. LuH. JiangY. First case of rhinocerebral mucormycosis caused by Lichtheimia ornata, with a review of Lichtheimia infections.Mycopathologia2020185355556710.1007/s11046‑020‑00451‑y 32388712
     [Google Scholar]
  21. VaeziA. WaltherG. KurzaiO. MahdiD. DadashzadehM. NasriE. DibaK. BadaliH. FakhimH. Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran.Mycoses202164778078710.1111/myc.13283 33835599
     [Google Scholar]
  22. JohnsonN.W. AmarasingheH. Global epidemiology.Oral and Oropharyngeal Cancer.CRC Press2018318
     [Google Scholar]
  23. MedhiB. BhattacharyyaA. SarmaP. SharmaD.J. DasK.K. KaurH. PrajapatM. KumarS. BansalS. PrakashA. AvtiP. ThotaP. ReddyD.H. GautamB.S. Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review.Indian J. Pharmacol.202153431732710.4103/ijp.ijp_419_21 34414911
     [Google Scholar]
  24. SkiadaA. Lass-FloerlC. KlimkoN. IbrahimA. RoilidesE. PetrikkosG. Challenges in the diagnosis and treatment of mucormycosis.Med. Mycol.201856Suppl. 1S93S10110.1093/mmy/myx101 29538730
     [Google Scholar]
  25. McCarthyM.W. KalasauskasD. PetraitisV. PetraitieneR. WalshT.J. Fungal infections of the central nervous system in children.J. Pediatric Infect. Dis. Soc.201763e123e13310.1093/jpids/pix059 28903523
     [Google Scholar]
  26. PanaZ.D. SeidelD. SkiadaA. GrollA.H. PetrikkosG. CornelyO.A. RoilidesE. Invasive mucormycosis in children: An epidemiologic study in European and non-European countries based on two registries.BMC Infect. Dis.201616166710.1186/s12879‑016‑2005‑1 27832748
     [Google Scholar]
  27. SteinbrinkJ.M. MiceliM.H. Mucormycosis.Infect. Dis. Clin. North Am.202135243545210.1016/j.idc.2021.03.009 34016285
     [Google Scholar]
  28. PaganoL. DragonettiG. De CarolisE. VeltriG. Del PrincipeM.I. BuscaA. Developments in identifying and managing mucormycosis in hematologic cancer patients.Expert Rev. Hematol.202013889590510.1080/17474086.2020.1796624 32664759
     [Google Scholar]
  29. MuggeoP. CaloreE. DecembrinoN. FrenosS. De LeonardisF. ColombiniA. PetruzzielloF. PerruccioK. BergerM. BurnelliR. ZanazzoG.A. SantoroN. CesaroS. Invasive mucormycosis in children with cancer: A retrospective study from the infection working group of Italian pediatric hematology oncology association.Mycoses201962216517010.1111/myc.12862 30338581
     [Google Scholar]
  30. DeshpandeV. Review of etiopathogenesis and early diagnosis of Mucormycosis.Eur. J. Mol. Clin. Med.20218420642073
     [Google Scholar]
  31. LakshminarayananK. MuruganD. VenkatesanJ. Vasanthakumari ThirumalaiswamyH. GadaisC. RangasamyL. Siderophore-conjugated antifungals: A strategy to potentially cure fungal infections.ACS Infect. Dis.20241082448246610.1021/acsinfecdis.4c00046 38905481
     [Google Scholar]
  32. MonikaP. ChandraprabhaM.N. Risks of mucormycosis in the current COVID-19 pandemic: A clinical challenge in both immunocompromised and immunocompetent patients.Mol. Biol. Rep.20224964977498810.1007/s11033‑022‑07160‑3 35107737
     [Google Scholar]
  33. Morales-FrancoB. Nava-VillalbaM. Medina-GuerreroE.O. Sánchez-NuñoY.A. Davila-VillaP. Anaya-AmbrizE.J. Charles-NiñoC.L. Host-pathogen molecular factors contribute to the pathogenesis of Rhizopus spp. in diabetes mellitus.Curr. Trop. Med. Rep.20218161710.1007/s40475‑020‑00222‑1 33500877
     [Google Scholar]
  34. NémethT. SperandioM. MócsaiA. Neutrophils as emerging therapeutic targets.Nat. Rev. Drug Discov.202019425327510.1038/s41573‑019‑0054‑z 31969717
     [Google Scholar]
  35. MontañoD.E. VoigtK. Host immune defense upon fungal infections with mucorales: Pathogen-immune cell interactions as drivers of inflammatory responses.J. Fungi20206317310.3390/jof6030173 32957440
     [Google Scholar]
  36. dos SantosA.R. Fraga-SilvaT.F. de Fátima Almeida-DonanzamD. dos SantosR.F. FinatoA.C. SoaresC.T. LaraV.S. AlmeidaN.L.M. AndradeM.I. de ArrudaO.S. de ArrudaM.S.P. VenturiniJ. IFN-γ mediated signaling improves fungal clearance in experimental pulmonary mucormycosis.Mycopathologia20221871153010.1007/s11046‑021‑00598‑2 34716549
     [Google Scholar]
  37. BrunetK. RammaertB. Mucormycosis treatment: Recommendations, latest advances, and perspectives.J. Mycol. Med.202030310100710.1016/j.mycmed.2020.101007 32718789
     [Google Scholar]
  38. YangN. ZhangL. FengS. Clinical features and treatment progress of invasive mucormycosis in patients with hematological malignancies.J. Fungi20239559210.3390/jof9050592 37233303
     [Google Scholar]
  39. BormanA.M. FraserM. PattersonZ. PalmerM.D. JohnsonE.M. In vitro antifungal drug resistance profiles of clinically relevant members of the mucorales (Mucoromycota) especially with the newer triazoles.J. Fungi20217427110.3390/jof7040271 33918216
     [Google Scholar]
  40. ClarkN.M. GrimS.A. LynchJ.P. III Posaconazole: use in the prophylaxis and treatment of fungal infections.Seminars in respiratory and critical care medicine.Stuttgart, GermanyThieme Medical Publishers2015
     [Google Scholar]
  41. RybakJ.M. MarxK.R. NishimotoA.T. RogersP.D. Isavuconazole: Pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent.Pharmacotherapy201535111037105110.1002/phar.1652 26598096
     [Google Scholar]
  42. JenksJ.D. SalzerH.J.F. PrattesJ. KrauseR. BuchheidtD. HoeniglM. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: Design, development, and place in therapy.Drug Des. Devel. Ther.2018121033104410.2147/DDDT.S145545 29750016
     [Google Scholar]
  43. BondarykM. KurzątkowskiW. StaniszewskaM. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: Mode of action and resistance development.Postepy Dermatol. Alergol.201330529330110.5114/pdia.2013.38358 24353489
     [Google Scholar]
  44. SchwarzP. CornelyO.A. DannaouiE. Antifungal combinations in Mucorales: A microbiological perspective.Mycoses201962974676010.1111/myc.12909 30830980
     [Google Scholar]
  45. MishraV. SinghM. MishraY. CharbeN. NayakP. SudhakarK. AljabaliA.A.A. ShahcheraghiS.H. BakshiH. Serrano-ArocaÁ. TambuwalaM.M. Nanoarchitectures in management of fungal diseases: An overview.Appl. Sci.20211115711910.3390/app11157119
     [Google Scholar]
  46. MandalD. Evaluating the impact of antifungal drugs on human health and exploring alternative treatments.Orient. J. Chem.202440310.13005/ojc/400302
     [Google Scholar]
  47. BorahP. Systemic and topical antifungal drugs.Medicinal Chemistry of Chemotherapeutic Agents.Elsevier202328531510.1016/B978‑0‑323‑90575‑6.00002‑8
     [Google Scholar]
  48. FisherM.C. Alastruey-IzquierdoA. BermanJ. BicanicT. BignellE.M. BowyerP. BromleyM. BrüggemannR. GarberG. CornelyO.A. GurrS.J. HarrisonT.S. KuijperE. RhodesJ. SheppardD.C. WarrisA. WhiteP.L. XuJ. ZwaanB. VerweijP.E. Tackling the emerging threat of antifungal resistance to human health.Nat. Rev. Microbiol.202220955757110.1038/s41579‑022‑00720‑1 35352028
     [Google Scholar]
  49. MuellerS.W. KedziorS.K. MillerM.A. ReynoldsP.M. KiserT.H. KrsakM. MolinaK.C. An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections.Expert Opin. Pharmacother.202122101355137110.1080/14656566.2021.1892075 33878996
     [Google Scholar]
  50. FaustinoC. PinheiroL. Lipid systems for the delivery of amphotericin B in antifungal therapy.Pharmaceutics20201212910.3390/pharmaceutics12010029 31906268
     [Google Scholar]
  51. TechapornroongM. SuankratayC. Alternate-day versus once-daily administration of amphotericin B in the treatment of cryptococcal meningitis: A randomized controlled trial.Scand. J. Infect. Dis.2007391089690110.1080/00365540701383147 17852947
     [Google Scholar]
  52. AljubranH.J. AlBahraniN.A. Use of miconazole cream as adjunctive therapy to treat isolated sinus mucormycosis: A case report and literature review.Cureus2024169e6924110.7759/cureus.69241 39398789
     [Google Scholar]
  53. TeixeiraM.M. CarvalhoD.T. SousaE. PintoE. New antifungal agents with azole moieties.Pharmaceuticals20221511142710.3390/ph15111427 36422557
     [Google Scholar]
  54. ChavanM.S.V. FathimaM.Z. FathimaM.Z. Nanostructured lipid carriers for the treatment of mucor mycosis: A comprehensive review.Afr. J. Biol. Sci.20246788693110.48047/AFJBS.6.7.2024.886‑931
     [Google Scholar]
  55. León-BuitimeaA. Garza-CervantesJ.A. Gallegos-AlvaradoD.Y. Osorio-ConcepciónM. Morones-RamírezJ.R. Nanomaterial-based antifungal therapies to combat fungal diseases Aspergillosis, Coccidioidomycosis, Mucormycosis, and Candidiasis.Pathogens20211010130310.3390/pathogens10101303 34684252
     [Google Scholar]
  56. IslamM.M. RaikwarS. Enhancement of oral bioavailability of protein and peptide by polysaccharide-based nanoparticles.Protein Pept. Lett.202431320922810.2174/0109298665292469240228064739 38509673
     [Google Scholar]
  57. ChatterjeeK. TanejaJ. KhullarS. PandeyA.K. Antifungal activity of silver nanoparticles on fungal isolates from patients of suspected mucormycosis.Int. Microbiol.202226114314710.1007/s10123‑022‑00280‑7 36251128
     [Google Scholar]
  58. SommerA. FörsterlingH-D. NaberK. PitchappanR. Pulmonary and intranasal delivery of thymoquinone-loaded nanoparticles for Mucormycosis & COVID-19.Precis. Nanomed.20214279580010.33218/001c.24963
     [Google Scholar]
  59. LiuJ. MaX. Amphotericin B colloidal dispersion: An effective drug for the treatment of mucormycosis in China.Front. Cell. Infect. Microbiol.202313114762410.3389/fcimb.2023.1147624 37265502
     [Google Scholar]
  60. GebremariamT. GuY. SinghS. KittT.M. IbrahimA.S. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis.J. Antimicrob. Chemother.202176102636263910.1093/jac/dkab233 34263306
     [Google Scholar]
  61. LanternierF. PoireeS. ElieC. Garcia-HermosoD. BakouboulaP. SitbonK. HerbrechtR. WolffM. RibaudP. LortholaryO. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis.J. Antimicrob. Chemother.201570113116312310.1093/jac/dkv236 26316385
     [Google Scholar]
  62. PonnaiyanD. AnithaC. PrakashP. SubramanianS. RughwaniR. KumarG. NandipatiS. Mucormycosis diagnosis revisited: Current and emerging diagnostic methodologies for the invasive fungal infection (Review).Exp. Ther. Med.20222514710.3892/etm.2022.11746 36569440
     [Google Scholar]
  63. KaurN. BainsA. KaushikR. DhullS.B. MelindaF. ChawlaP. A review on antifungal efficiency of plant extracts entrenched polysaccharide-based nanohydrogels.Nutrients2021136205510.3390/nu13062055 34203999
     [Google Scholar]
  64. AkramM.W. JamshaidH. RehmanF.U. ZaeemM. KhanJ. ZebA. Transfersomes: A revolutionary nanosystem for efficient transdermal drug delivery.AAPS PharmSciTech2021231710.1208/s12249‑021‑02166‑9 34853906
     [Google Scholar]
  65. MatharooN. MohdH. Michniak-KohnB. Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developments.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.2024161e191810.1002/wnan.1918 37527953
     [Google Scholar]
  66. MarenaG.D. RamosM.A.S. CarvalhoG.C. JuniorJ.A.P. ResendeF.A. CorrêaI. OnoG.Y.B. Sousa AraujoV.H. de CamargoB.A.F. BauabT.M. ChorilliM. Natural product‐based nanomedicine applied to fungal infection treatment: A review of the last 4 years.Phytother. Res.20223672710274510.1002/ptr.7460 35643985
     [Google Scholar]
  67. HussainA. SinghV.K. SinghO.P. ShafaatK. KumarS. AhmadF.J. Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B.Drug Deliv.20162383101311010.3109/10717544.2016.1153747 27854145
     [Google Scholar]
  68. YangQ. LiuS. GuY. TangX. WangT. WuJ. LiuJ. Development of sulconazole-loaded nanoemulsions for enhancement of transdermal permeation and antifungal activity.Int. J. Nanomedicine2019143955396610.2147/IJN.S206657 31239665
     [Google Scholar]
/content/journals/aia/10.2174/0122113525373696250623070215
Loading
Recent Approach for an Effective Treatment of Mucormycosis and Future Directions
Anti Infect. Agents 24, E22113525373696 (2026); https://doi.org/10.2174/0122113525373696250623070215
/content/journals/aia/10.2174/0122113525373696250623070215
/content/journals/aia/10.2174/0122113525373696250623070215
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): amphotericin B; antifungal agents; fungal infection; mucorales; Mucormycosis; nanotechnology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test